Protagonist Long Term Debt from 2010 to 2024
| PTGX Stock | USD 29.81 1.66 5.90% |
Long Term Debt | First Reported 2010-12-31 | Previous Quarter 11.3 M | Current Value 11.8 M | Quarterly Volatility 4.6 M |
Check Protagonist Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagonist Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.5 M, Interest Expense of 4.1 M or Selling General Administrative of 18 M, as well as many indicators such as Price To Sales Ratio of 20.61, Dividend Yield of 0.0 or PTB Ratio of 4.06. Protagonist financial statements analysis is a perfect complement when working with Protagonist Therapeutics Valuation or Volatility modules.
Protagonist | Long Term Debt |
Latest Protagonist Therapeutics' Long Term Debt Growth Pattern
Below is the plot of the Long Term Debt of Protagonist Therapeutics over the last few years. Long-term debt is a debt that Protagonist Therapeutics has held for over one year. Long-term debt appears on Protagonist Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Protagonist Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. It is debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years. Protagonist Therapeutics' Long Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagonist Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Long Term Debt | 10 Years Trend |
|
Long Term Debt |
| Timeline |
Protagonist Long Term Debt Regression Statistics
| Arithmetic Mean | 5,653,157 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 81.06 | |
| Mean Deviation | 4,331,634 | |
| Median | 2,123,000 | |
| Standard Deviation | 4,582,575 | |
| Sample Variance | 21T | |
| Range | 11.8M | |
| R-Value | 0.84 | |
| Mean Square Error | 6.8T | |
| R-Squared | 0.70 | |
| Significance | 0.0001 | |
| Slope | 856,969 | |
| Total Sum of Squares | 294T |
Protagonist Long Term Debt History
Other Fundumenentals of Protagonist Therapeutics
About Protagonist Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Protagonist Therapeutics income statement, its balance sheet, and the statement of cash flows. Protagonist Therapeutics investors use historical funamental indicators, such as Protagonist Therapeutics's Long Term Debt, to determine how well the company is positioned to perform in the future. Although Protagonist Therapeutics investors may use each financial statement separately, they are all related. The changes in Protagonist Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Protagonist Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Protagonist Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Protagonist Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Long Term Debt | 11.3 M | 11.8 M | |
| Long Term Debt Total | 11.3 M | 6.6 M | |
| Short and Long Term Debt Total | 1.1 M | 1.1 M | |
| Long Term Debt To Capitalization | (0) | (0) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| CRM | Salesforce | |
| GOOG | Alphabet Inc Class C |
Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.